GleamWall
中文EN

XFOR X4 Pharmaceuticals, Inc

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1501697 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY73.7%
TTM net income YoY15.3%
TTM EPS YoY106.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin68.8%
Operating margin-812.0%
Net margin-813.3%
FCF margin—
EBITDA margin-794.1%

Returns

ROE-80.3%
ROA-40.7%
ROIC (approx.)-134.7%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets40.1%
Debt / equity0.54x
Current ratio13.22x
Interest coverage-9.26x

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-2.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.80M$2.40M$2.50M$2.20M$1.60M$1.70M$900,000$1.50M
Cost of revenue$513,000$1.62M$598,000$364,000$351,000$326,000$4.72M$302,000
Gross profit$2.29M$783,000$1.90M$1.84M$1.25M$1.37M-$3.82M$1.20M
R&D expense$13.34M$15.08M$15.45M$18.52M$17.34M$18.35M$18.51M$21.70M
SG&A expense$9.01M$8.50M$6.97M$7.38M$11.59M$9.53M$15.02M$15.14M
Operating income-$19.99M-$16.39M-$20.31M-$23.70M-$27.51M-$26.23M-$9.44M-$35.72M
Interest expense$2.19M$2.16M$2.13M$2.19M$2.26M$2.23M$2.20M$2.30M
Pretax income-$20.20M-$16.16M-$20.24M-$23.93M-$29.84M-$25.70M$316,000-$39.56M
Income tax$3,000$2,000$0$0-$30,000$37,000$34,000$258,000
Net income-$20.20M-$16.16M-$20.24M-$23.93M-$29.82M-$25.74M$282,000-$39.82M
EBITDA-$19.66M-$15.39M-$20.08M-$23.48M-$27.29M-$25.88M-$8.97M-$35.44M
EPS (basic)-0.16-0.13-0.16—-0.69-3.470.04—
EPS (diluted)-0.16-0.13-0.16—-0.69-3.470.04—
Weighted avg. shares (diluted)126.52M126.34M126.29M—43.27M7.41M6.87M—
Balance sheet
Cash & equivalents$185.80M$195.09M$216.91M$217.05M$70.44M$40.02M$41.04M$56.48M
Receivables$1.47M$2.05M$1.11M$573,000$891,000$1.15M$509,000$1.07M
Inventory$5.51M$5.50M$4.64M$4.48M$4.08M$3.17M$3.09M$2.82M
Current assets$198.13M$218.85M$241.98M$261.58M$132.81M$72.94M$95.70M$112.17M
PP&E, net$57,000$111,000$146,000$182,000$218,000$254,000$487,000$776,000
Goodwill$17.35M$17.35M$17.35M$17.35M$17.35M$17.35M$17.35M$17.35M
Intangibles$12.82M$13.10M$9.06M$9.25M$9.44M$9.62M$9.81M$10.00M
Total assets$231.82M$253.06M$270.28M$290.46M$163.56M$105.17M$130.01M$146.45M
Current liabilities$14.98M$19.37M$23.77M$25.76M$23.51M$22.90M$25.88M$32.88M
Long-term debt$75.00M$75.00M$75.00M$75.00M$75.00M$75.00M$75.00M$75.00M
Total debt$75.00M$75.00M$75.00M$75.00M$75.00M$75.00M$75.00M$75.00M
Total liabilities$92.93M$97.61M$101.83M$104.17M$101.94M$101.20M$107.07M$124.30M
Shareholders' equity$138.88M$155.45M$168.45M$186.29M$61.62M$3.97M$22.94M$22.15M
Net debt-$110.80M-$120.09M-$141.91M-$142.05M$4.57M$34.98M$33.96M$18.52M
Shares outstanding100.90M96.11M94.32M90.91M25.15M7.96M5.79M5.70M
Cash flow statement
Operating cash flow-$20.19M-$20.79M-$19.60M-$15.53M-$27.82M-$29.90M-$12.37M-$32.99M
Capital expenditure———$0$0$0$0$41,000
Free cash flow———-$15.53M-$27.82M-$29.90M-$12.37M-$33.04M
Investing cash flow$11.00M-$1.00M$19.25M$16.85M-$28.67M$23.11M-$3.14M-$8.62M
Financing cash flow-$112,000$75,000$2,000$146.09M$86.91M$5.63M$0$135,000
Depreciation & amortization$331,000$997,000$223,000$223,000$223,000$355,000$476,000$273,000
Stock-based compensation$3.50M$3.09M$2.41M$2.27M$760,000$748,000$519,000$2.22M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.